Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
RGNX
STRONG SELLREGENXBIO Inc. · Healthcare · United States · $623M · Avg Vol: $26M/d
COMPANY DESCRIPTION
REGENXBIO Inc. is a leading clinical-stage biotechnology company focused on the development of gene therapies using its proprietary NAV® AAV gene delivery platform. The company's pipeline targets severe genetic diseases across ophthalmology, neurodegenerative diseases, and other therapeutic areas, with multiple programs in clinical development. REGENXBIO maintains a strong competitive moat through its extensive patent estate and broad licensing strategy for its advanced gene delivery technology.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 112.7M | 90.2M | 83.3M | 170.4M | 14.8% | 87.8M | 237.9M | 247.5M | 20.5% |
| EPS | -6.50 | -6.02 | -4.59 | -3.76 | — | -5.84 | -2.79 | -2.54 | — |
| Shares | 43.3M | 44.0M | 49.5M | 50.9M | +17.5% | 54.0M | — | — | — |
| Debt | 94.8M | 89.3M | 82.0M | 73.5M | -8.1% | 248.4M | — | — | — |
| Equity | 516.2M | 311.7M | 259.7M | 102.7M | -41.6% | — | — | — | — |
| Op CF | -207.5M | -218.4M | -173.1M | -124.0M | — | -233.8M | — | — | — |
| Inv CF | -11.9M | 190.9M | 103.4M | -15.9M | — | — | — | — | — |
| Fin CF | -28.8M | -35.0M | 92.7M | 116.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of RGNX are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| RGNX | REGENXBIO Inc.(you) | $623M | 7 | STRONG SELL |
| SPRY | ARS Pharmaceuticals, Inc. | $590M | 5 | STRONG SELL |
| 0IL8.L | Kyntra Bio, Inc. | $666M | 10 | STRONG SELL |
| VSTM | Verastem, Inc. | $532M | 10 | STRONG SELL |
| PRME | Prime Medicine, Inc. | $533M | 3 | STRONG SELL |
| PROK | ProKidney Corp. | $453M | 7 | STRONG SELL |
| ALT | Altimmune, Inc. | $539M | 12 | STRONG SELL |
| CTMX | CytomX Therapeutics, Inc. | $705M | 13 | STRONG SELL |
| SGP | SpyGlass Pharma, Inc. | $685M | 13 | STRONG SELL |
| EVMN | Evommune, Inc. | $409M | 8 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%